-
公开(公告)号:US08293748B2
公开(公告)日:2012-10-23
申请号:US13121999
申请日:2009-10-02
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/496 , A61K31/505 , A61K31/4427 , C07D403/02 , C07D403/14 , C07D401/02 , C07D401/14
CPC分类号: C07D401/14 , C07D401/12 , C07D403/12
摘要: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
摘要翻译: 特别是提供式(I)化合物,其中R 1,Ar,L,X,R 3和Q如说明书中用于治疗,特别是治疗炎性疾病的说明书中所定义。
-
公开(公告)号:US20130012512A1
公开(公告)日:2013-01-10
申请号:US13616696
申请日:2012-09-14
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/4439 , C07D405/14 , C07D413/14 , A61K31/5377 , A61P11/06 , A61K31/496 , C07D403/12 , A61K31/506 , A61K31/4178 , A61P11/00 , C07D401/12 , C07D401/14
CPC分类号: C07D401/14 , C07D401/12 , C07D403/12
摘要: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
-
公开(公告)号:US20110294812A1
公开(公告)日:2011-12-01
申请号:US13133998
申请日:2009-12-11
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/4439 , C07D405/14 , C07D413/14 , C07D401/14 , A61K31/5377 , A61K31/496 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P1/04 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , C07D401/12
CPC分类号: C07D401/12 , C07D401/14 , C07D403/12
摘要: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐,其包括其所有的立体异构体,互变异构体和同位素衍生物,其是p38丝裂原活化蛋白激酶的抑制剂(本文称为p38 MAP激酶抑制剂), 特别是其α和γ激酶亚型,以及它们在治疗中的用途,包括药物组合,特别是治疗炎症性疾病,包括肺炎性疾病如COPD。
-
公开(公告)号:US20110212962A1
公开(公告)日:2011-09-01
申请号:US13121999
申请日:2009-10-02
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/5377 , C07D401/12 , C07D405/14 , C07D413/14 , C07D401/14 , C07D403/12 , A61K31/4439 , A61K31/496 , A61K31/506 , A61K31/4178 , A61P11/00 , A61P11/08 , A61P11/06 , A61P11/02 , A61P17/00 , A61P17/06 , A61P29/00 , A61P1/18 , A61P35/00 , A61P27/14 , A61P35/04 , A61P19/02
CPC分类号: C07D401/14 , C07D401/12 , C07D403/12
摘要: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
摘要翻译: 特别是提供式(I)化合物,其中R 1,Ar,L,X,R 3和Q如在说明书中用于治疗,特别是治疗炎性疾病的说明书中所定义。
-
公开(公告)号:US08618140B2
公开(公告)日:2013-12-31
申请号:US13616696
申请日:2012-09-14
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/4439 , C07D401/02
CPC分类号: C07D401/14 , C07D401/12 , C07D403/12
摘要: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
-
公开(公告)号:US08299073B2
公开(公告)日:2012-10-30
申请号:US13133998
申请日:2009-12-11
申请人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
发明人: Kazuhiro Ito , Peter Strong , William Garth Rapeport , Peter John Murray , John King-Underwood , Jonathan Gareth Williams , Stuart Thomas Onions , Simon Christopher Hirst , David Michel Adrien Taddei , Catherine Elisabeth Charron
IPC分类号: A61K31/5377 , A61K31/505 , A61K31/445 , A61K31/4427 , A61K31/496 , C07D413/14 , C07D403/02 , C07D213/02 , C07D211/06 , C07D401/02 , C07D401/14
CPC分类号: C07D401/12 , C07D401/14 , C07D403/12
摘要: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐,其包括其所有的立体异构体,互变异构体和同位素衍生物,其是p38丝裂原活化蛋白激酶的抑制剂(本文称为p38 MAP激酶抑制剂), 特别是其α和γ激酶亚型,以及它们在治疗中的用途,包括药物组合,特别是治疗炎症性疾病,包括肺炎性疾病如COPD。
-
公开(公告)号:US20100087515A1
公开(公告)日:2010-04-08
申请号:US12513206
申请日:2007-10-29
申请人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathan Gareth Williams
发明人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathan Gareth Williams
IPC分类号: A61K31/381 , C07D333/38 , C12N9/99 , A61P35/00 , A61P37/00 , A61P29/00 , A61P1/00 , A61P11/00
CPC分类号: C07D333/38
摘要: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═P)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.
摘要翻译: 式(IA)或(IB)的化合物是IkB激酶(IKK)活性的抑制剂,可用于治疗自身免疫性和炎性疾病:式(A)和(B)其中R 7为氢或任选取代的(C1- C6)烷基; 环A是任选取代的5-13个环原子的芳基或杂芳基环; Z是(a)式R1R2CHNH-Y-L1-X1-(CH2)z-的基团,其中:z为0或1; R 1是羧酸基团(-COOH)或可被一个或多个细胞内酯酶水解成羧酸基团的酯基; R2是天然或非天然α氨基酸的侧链; Y是键,-C(= O) - , - S(= O)2 - , - C(= O)O-,-C(= O)NR 3 - , - C(= NH)-NR 3或-S(= O)2 NR 3 - ,其中R 3是氢或任选取代的C 1 -C 6烷基; L1是式 - (Alk1)m(Q)(Alk2)p的二价连接基团,其中m,n,p,Q,Alk1和Alk2如权利要求中所定义。
-
公开(公告)号:US08003695B2
公开(公告)日:2011-08-23
申请号:US12513206
申请日:2007-10-29
申请人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathan Gareth Williams
发明人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathan Gareth Williams
IPC分类号: A61K31/381 , C07D333/38
CPC分类号: C07D333/38
摘要: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═P)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.
摘要翻译: 式(IA)或(IB)的化合物是IkB激酶(IKK)活性的抑制剂,可用于治疗自身免疫性和炎性疾病:式(A)和(B)其中R 7为氢或任选取代的(C1- C6)烷基; 环A是任选取代的5-13个环原子的芳基或杂芳基环; Z是(a)式R1R2CHNH-Y-L1-X1-(CH2)z-的基团,其中:z为0或1; R 1是羧酸基团(-COOH)或可被一个或多个细胞内酯酶水解成羧酸基团的酯基; R2是天然或非天然α氨基酸的侧链; Y是键,-C(= O) - , - S(= O)2 - , - C(= O)O-,-C(= O)NR 3 - , - C(= NH)-NR 3或-S(= O)2 NR 3 - ,其中R 3是氢或任选取代的C 1 -C 6烷基; L1是式 - (Alk1)m(Q)(Alk2)p的二价连接基团,其中m,n,p,Q,Alk1和Alk2如权利要求中所定义。
-
公开(公告)号:US20100069473A1
公开(公告)日:2010-03-18
申请号:US12447271
申请日:2007-10-29
申请人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathon Gareth Williams
发明人: David Festus Charles Moffat , Stephen John Davies , Michael Hugh Charlton , Simon Christopher Hirst , Stuart Thomas Onions , Jonathon Gareth Williams
IPC分类号: A61K31/381 , C07D333/36 , C12N9/99 , A61P35/00 , A61P37/00 , A61P29/00 , A61P11/00 , A61P17/00 , A61P3/10
CPC分类号: C07D333/38
摘要: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L1-Y1—(CH2)z—, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R6 is hydrogen, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl; Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR4—, wherein R3 and R4 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims.
摘要翻译: 式(IA)或(IB)的化合物是IkB激酶(IKK)活性的抑制剂,可用于治疗自身免疫性和炎性疾病:其中R 7为氢或任选取代的(C 1 -C 6)烷基; 环A是任选取代的5-13个环原子的芳基或杂芳基环; Z是式R-L1-Y1-(CH2)z-的基团,其中:z是0或1; R是式(X)或(Y)的基团,R 1是羧酸基团(-COOH)或可被一个或多个细胞内酯酶水解成羧酸基团的酯基; R 6是氢或任选取代的C 1 -C 6烷基,C 3 -C 7环烷基,芳基或杂芳基或 - (C = O)R 3, - (C = O)OR 3或 - (C = O)NR 3,其中R 3是氢或 任选取代的(C 1 -C 6)烷基; Y1是一个键, - (C = O) - , - S(O 2) - , - C(= O)O-,-OC(= O) - , - (C = O)NR 3 - , - NR 3 (O) - , - S(O 2)NR 3 - , - NR 3 S(O 2) - 或-NR 3(C = O)NR 4 - ,其中R 3和R 4独立地是氢或任选取代的(C 1 -C 6) 式 - (Alk1)m(Q)n(Alk2)p的二价连接基团其中m,n,p,Q,Alk1和Alk2如权利要求中所定义。
-
10.
公开(公告)号:US08217050B2
公开(公告)日:2012-07-10
申请号:US12513658
申请日:2007-11-05
IPC分类号: C07D473/34 , A61K31/52 , A61P11/06 , A61P37/06 , A61P19/02 , A61P3/10 , A61P17/06 , C07F7/18 , C07F7/10
CPC分类号: C07D473/34
摘要: The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, L1, Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.
摘要翻译: 本发明提供一种化合物,其为(a)式(I)的氨基酸衍生物或其互变异构体,或(b)其药学上可接受的盐,N-氧化物,水合物或溶剂合物:其中R1,R2,L1,Het A,x,y和W如本文所定义。 该化合物可用于治疗由HSP90介导的疾病。
-
-
-
-
-
-
-
-
-